Skip to Main Content

Good morning. Elizabeth Cooney here, about to relinquish the guest-host chair when Ed Silverman wraps up his tour of JPM in San Francisco. Lots of news there, lots of news everywhere. Here we go:

Verily, one of the most-talked-about debutants at this year’s J.P. Morgan ball, stumbled into apparent tension in its partnership with Dexcom (DXCM), STAT scoops. San Diego-based Dexcom launched in 2015 with the goal of creating a low-cost, disposable continuous glucose monitor for people with type 2 diabetes, the most common form of the disease that is tied to obesity and low activity levels. Verily, the Alphabet (GOOG) life sciences spinout, has embarked on a partnership with the diabetes device company to make a first-of-its-kind glucose monitor. But Verily CEO Andy Conrad said and showed more in a standing-room-only presentation than Dexcom CEO Kevin Sayer would have liked.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!